Monte Rosa Closes Global License Agreement With Novartis

MT Newswires Live12-11

Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.

Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.

Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.

The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.

Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.

The agreement was first announced in October.

Shares of Monte Rosa jumped over 8% in recent Wednesday premarket activity, while Novartis' stock edged up by 0.1%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490596338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490596338","market":"sh","top_or_hot":-1,"title":"Monte Rosa Closes Global License Agreement With Novartis","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.</p><p>Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.</p><p>Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.</p><p>The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.</p><p>Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.</p><p>The agreement was first announced in October.</p><p>Shares of Monte Rosa jumped over 8% in recent Wednesday premarket activity, while Novartis' stock edged up by 0.1%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Closes Global License Agreement With Novartis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Closes Global License Agreement With Novartis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.Under ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490596338","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490596338","pubTimestamp":1733921115,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Monte Rosa Therapeutics  said Wednesday it has closed its development and commercialization license deal with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160.Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.The agreement was first announced in October.Shares of Monte Rosa ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","BK4578":"CAR-T","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","NVS":"诺华","GLUE":"Monte Rosa Therapeutics","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4539":"次新股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Monte Rosa与诺华达成全球许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"GLUE":0.9},"content_text":"Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.The agreement was first announced in October.Shares of Monte Rosa jumped over 8% in recent Wednesday premarket activity, while Novartis' stock edged up by 0.1%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490596338"}